Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food

Neuropsychopharmacology

Volumn 33, Issue 3, 2008, Pages 524-535

  Cottone, Pietro ^a,b   Sabino, Valentina ^a   Steardo, Luca ^b   Zorrilla, Eric P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

opioid receptor or opioid receptor antagonist; Anticipatory negative contrast; Binge eating disorder; Bulimia OR bulimic; Food intake OR feeding; Hedonic evaluation; Limited access; Nalmefene; Palatability; Visceral obesity OR obese

Indexed keywords

GHRELIN; GROWTH HORMONE; LEPTIN; NALMEFENE; OPIATE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BINGE EATING DISORDER; CONTROLLED STUDY; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; MACRONUTRIENT; NONHUMAN; PRIORITY JOURNAL; RAT;

ADIPOSITY; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BODY WEIGHT; EATING; FEEDING BEHAVIOR; FEMALE; FOOD; FOOD PREFERENCES; GHRELIN; GROWTH HORMONE; LEPTIN; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RATS; RATS, WISTAR; RECEPTORS, OPIOID;

EID: 38149054861     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301430     Document Type: Article

References (89)

1. Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Elsworth JD et al (2006). Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest 116: 3229-3239.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edn) text revision. American Psychiatric Press: Washington, DC.
3. Barbano MF, Cador M (2006). Differential regulation of the consummatory, motivational and anticipatory aspects of feeding behavior by dopaminergic and opioidergic drugs. Neuropsychopharmacology 31: 1371-1381.
4. Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ (2005). Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 30: 2254-2262.
5. Bates SH, Myers MG (2003). The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab 14: 447-452.
6. Batista MR, Ferraz M, Bazotte RB (1997). Are physiological changes in meal-fed rats determined by the amount of food ingested in the last meal or due to feeding schedule? Physiol Behav 62: 249-253.
7. Blazer DG, Kessler RC, McGonagle KA, Swartz MS (1994). The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 151: 979-986.
8. Calderon LL, Yu CK, Jambazian P (2004). Dieting practices in high school students. J Am Diet Assoc 104: 1369-1374.
9. Chaouloff F (1994). Failure to find behavioural differences between lean and obese Zucker rats exposed to novel environments. Int J Obes Relat Metab Disord 18: 780-782.
10. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al (1996). Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295.
11. Cooper SJ (2004). Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. Eur J Pharmacol 500: 37-49.
12. Cooper SJ, Francis RL (1979). Effects of acute or chronic administration of chlordiazepoxide on feeding parameters using two food textures in the rat. J Pharm Pharmacol 31: 743-746.
13. Corwin RL, Buda-Levin A (2004). Behavioral models of binge-type eating. Physiol Behav 82: 123-130.
14. Corwin RL (2006). Bingeing rats: a model of intermittent excessive behavior? Appetite 46: 11-15.
15. Cruz AP, Frei F, Graeff FG (1994). Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49: 171-176.
16. Culpepper-Morgan JA, Holt PR, LaRoche D, Kreek MJ (1995). Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig. Life Sci 56: 1187-1192.
17. de Zwaan M, Mitchell JE (1992). Opiate antagonists and eating behavior in humans: a review. J Clin Pharmacol 32: 1060-1072.
18. Despres JP (1993). Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9: 452-459.
19. Drazen DL, Vahl TP, D'Alessio DA, Seeley RJ, Woods SC (2006). Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology 147: 23-30.
20. Druce MR, Neary NM, Small CJ, Milton J, Monteiro M, Patterson M et al (2006). Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers. Int J Obes (Lond) 30: 293-296.
21. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F (1994). Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271: 1630-1637.
22. Falorni A, Kassi G, Murdolo G, Calcinaro F (1998). Controversies on humoral immune markers of insulin-dependent diabetes mellitus. J Pediatr Endocrinol Metab 11(Suppl 2): 307-317.
23. Fernandes C, File SE (1996). The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav 54: 31-40.
24. Flaherty CF, Checke S (1982). Anticipation of incentive gain. Anim Learn Behav 10: 177-182.
25. Flaherty CF, Rowan GA (1986). Successive, simultaneous, and anticipatory contrast in the consumption of saccharin solutions. J Exp Psychol Anim Behav Process 12: 381-393.
26. Flaherty CF, Coppotelli C, Grigson PS, Colin M, Flaherty JE (1995). Investigation of the devaluation interpretation of anticipatory negative contrast. J Exp Psychol Anim Behav Process 21: 229-247.
27. Fletcher BC, Pine KJ, Woodbridge Z, Nash A (2007). How visual images of chocolate affect the craving and guilt of female dieters. Appetite 48: 211-217.
28. Gluck ME (2006). Stress response and binge eating disorder. Appetite 46: 26-30.
29. Gola M, Bonadonna S, Doga M, Mazziotti G, Giustina A (2005). Cardiovascular risk in aging and obesity: is there a role for GH. J Endocrinol Invest 28: 759-767.
30. Gonzalez VM, Vitousek KM (2004). Feared food in dieting and non-dieting young women: a preliminary validation of the Food Phobia Survey. Appetite 43: 155-173.
31. Guha PK, Villarreal D, Reams GP, Freeman RH (2003). Role of leptin in the regulation of body fluid volume and pressures. Am J Ther 10: 211-218.
32. Hagan MM, Moss DE (1997). Persistence of binge-eating patterns after a history of restriction with intermittent bouts of refeeding on palatable food in rats: implications for bulimia nervosa. Int J Eat Disord 22: 411-420.
33. Hagan MM, Chandler PC, Wauford PK, Rybak RJ, Oswald KD (2003). The role of palatable food and hunger as trigger factors in an animal model of stress induced binge eating. Int J Eat Disord 34: 183-197.
34. Hao J, Cabeza de Vaca S, Pan Y, Carr KD (2006). Effects of central leptin infusion on the reward-potentiating effect of D-amphetamine. Brain Res 1087: 123-133.
35. Harris RB, Martin RJ (1984). Recovery of body weight from below 'set point' in mature female rats. J Nutr 114: 1143-1150.
36. Hartz SM, Ben-Shahar Y, Tyler M (2001). Logistic growth curve analysis in associative learning data. Anim Cogn 3: 185-189.
37. Hoffman AR (2005). Treatment of the adult growth hormone deficiency syndrome: directions for future research. Growth Horm IGF Res 15(Suppl A): 48-52.
38. Hommel JD, Trinko R, Sears RM, Georgescu D, Liu ZW, Gao XB et al (2006). Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 51: 801-810.
39. Howard CE, Porzelius LK (1999). The role of dieting in binge eating disorder: etiology and treatment implications. Clin Psychol Rev 19: 25-44.
40. Hudson JI, Hiripi E, Pope Jr HG, Kessler RC (2007). The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 61: 348-358.
41. Hunt T, Poulos CX, Cappell H (1988). Benzodiazepine-induced hyperphagia: a test of the hunger-mimetic model. Pharmacol Biochem Behav 30: 515-518.
42. Inoue K, Zorrilla EP, Tabarin A, Valdez GR, Iwasaki S, Kiriike N et al (2004). Reduction of anxiety after restricted feeding in the rat: implication for eating disorders. Biol Psychiatry 55: 1075-1081.
43. Jarosz PA, Sekhon P, Coscina DV (2006). Effect of opioid antagonism on conditioned place preferences to snack foods. Pharmacol Biochem Behav 83: 257-264.
44. June HL, Grey C, Warren-Reese C, Durr LF, Ricks-Cord A, Johnson A et al (1998). The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res 22: 2174-2185.
45. Kales EF (1990). Macronutrient analysis of binge eating in bulimia. Physiol Behav 48: 837-840.
46. Kanarek RB, Orthen-Gambill N (1982). Differential effects of sucrose, fructose and glucose on carbohydrate-induced obesity in rats. J Nutr 112: 1546-1554.
47. Kanarek RB, Aprille JR, Hirsch E, Gualtiere L, Brown CA (1987). Sucrose-induced obesity: effect of diet on obesity and brown adipose tissue. Am J Physiol 253: R158-R166.
48. Kas MJ, van den BR, Baars AM, Lubbers M, Lesscher HM, Hillebrand JJ et al (2004). Mu-opioid receptor knockout mice show diminished food-anticipatory activity. Eur J Neurosci 20: 1624-1632.
49. Kauffman NA, Herman CP, Polivy J (1995). Hunger-induced finickiness in humans. Appetite 24: 203-218.
50. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M (2002). Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 76: 365-377.
51. Kelley AE, Baldo BA, Pratt WE, Will MJ (2005). Corticostriatal- hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav 86: 773-795.
52. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19.
53. Knight LJ, Boland FJ (1989). Restrained eating: an experimental disentanglement of the disinhibiting variables of perceived calories and food type. J Abnorm Psychol 98: 412-420.
54. 3H]-DAGO) receptors in hypothalamic micropunches from maturing female rats: comparison between SDZ 210-096 and nalmefene. Neuropeptides 21: 175-182.
55. Levin BE, Richard D, Michel C, Servatius R (2000). Differential stress responsivity in diet-induced obese and resistant rats. Am J Physiol Regul Integr Comp Physiol 279: R1357-R1364.
56. MacDonald AF, Billington CJ, Levine AS (2003). Effects of the opioid antagonist naltrexone on feeding induced by DAMGO in the ventral tegmental area and in the nucleus accumbens shell region in the rat. Am J Physiol Regul Integr Comp Physiol 285: R999-R1004.
57. MacDonald AF, Billington CJ, Levine AS (2004). Alterations in food intake by opioid and dopamine signaling pathways between the ventral tegmental area and the shell of the nucleus accumbens. Brain Res 1018: 78-85.
58. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y et al (1995). Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-1161.
59. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B et al (1994). A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 18: 1162-1167.
60. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB (1999). A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56: 719-724.
61. Michel ME, Bolger G, Weissman BA (1985). Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 7: 175-177.
62. Mitchell GL, Brunstrom JM (2005). Everyday dietary behaviour and the relationship between attention and meal size. Appetite 45: 344-355.
63. Olszewski PK, Levine AS (2007). Central opioids and consumption of sweet tastants: when reward outweighs homeostasis. Physiol Behav, in press.
64. Pico C, Oliver P, Sanchez J, Palou A (2003). Gastric leptin: a putative role in the short-term regulation of food intake. Br J Nutr 90: 735-741.
65. Pike KM, Dohm FA, Striegel-Moore RH, Wilfley DE, Fairburn CG (2001). A comparison of black and white women with binge eating disorder. Am J Psychiatry 158: 1455-1460.
66. Pliner P, Herman CP, Polivy J (1990). Palatability as a determinant of eating: Finickiness as a function of taste, hunger, and the prospect of good food. In: ED Capaldi and TL Powley (eds). Taste, Experience, and Feeding: Development and Learning. American Psychological Association: Washington, DC. pp 210-226.
67. Proulx K, Vahl TP, Drazen DL, Woods SC, Seeley RJ (2005). The effect of adrenalectomy on ghrelin secretion and orexigenic action. J Neuroendocrinol 17: 445-451.
68. Scacchi M, Pincelli AI, Cavagnini F (1999). Growth hormone in obesity. Int J Obes Relat Metab Disord 23: 260-271.
69. Sherwin RS, Hendler R, DeFronzo R, Wahren J, Felic P (1977). Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin. Proc Natl Acad Sci USA 74: 348-352.
70. Shizgal P, Fulton S, Woodside B (2001). Brain reward circuitry and the regulation of energy balance. Int J Obes Relat Metab Disord 25(Suppl 5): S17-S21.
71. Shrout PE, Fleiss JL (1979). Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86: 420-428.
72. Smith DE, Marcus MD, Lewis CE, Fitzgibbon M, Schreiner P (1998). Prevalence of binge eating disorder, obesity, and depression in a biracial cohort of young adults. Ann Behav Med 20: 227-232.
73. Smith KS, Berridge KC (2007). Opioid limbic circuit for reward: interaction between hedonic hotspots of nucleus accumbens and ventral pallidum. J Neurosci 27: 1594-1605.
74. Specker S, de ZM, Raymond N, Mitchell J (1994). Psychopathology in subgroups of obese women with and without binge eating disorder. Compr Psychiatry 35: 185-190.
75. Stirling LJ, Yeomans MR (2004). Effect of exposure to a forbidden food on eating in restrained and unrestrained women. Int J Eat Disord 35: 59-68.
76. Taber MT, Zernig G, Fibiger HC (1998). Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens. Brain Res 785: 24-30.
77. Taylor AE, Hubbard J, Anderson EJ (1999). Impact of binge eating on metabolic and leptin dynamics in normal young women. J Clin Endocrinol Metab 84: 428-434.
78. Tschop M, Smiley DL, Heiman ML (2000). Ghrelin induces adiposity in rodents. Nature 407: 908-913.
79. Unterwald EM, Tsukada H, Kakiuchi T, Kosugi T, Nishiyama S, Kreek MJ (1997). Use of positron emission tomography to measure the effects of nalmefene on D1 and D2 dopamine receptors in rat brain. Brain Res 775: 183-188.
80. Wajchenberg BL (2000). Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21: 697-738.
81. Ward HG, Nicklous DM, Aloyo VJ, Simansky KJ (2006). Mu-opioid receptor cellular function in the nucleus accumbens is essential for hedonically driven eating. Eur J Neurosci 23: 1605-1613.
82. Wardle J, Guthrie CA, Sanderson S, Rapoport L (2001). Development of the children's eating behaviour questionnaire. J Child Psychol Psychiatry 42: 963-970.
83. Woolley JD, Lee BS, Fields HL (2006). Nucleus accumbens opioids regulate flavor-based preferences in food consumption. Neuroscience 143: 309-317.
84. Wortley KE, del Rincon JP, Murray JD, Garcia K, Iida K, Thorner MO et al (2005). Absence of ghrelin protects against early-onset obesity. J Clin Invest 115: 3573-3578.
85. Yanovski SZ (2003). Binge eating disorder and obesity in 2003: could treating an eating disorder have a positive effect on the obesity epidemic? Int J Eat Disord 34(Suppl): S117-S120.
86. Yeomans MR, Gray RW (2002). Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 26: 713-728.
87. Yeomans MR, Wright P (1991). Lower pleasantness of palatable foods in nalmefene-treated human volunteers. Appetite 16: 249-259.
88. Yeomans MR, Wright P, Macleod HA, Critchley JA (1990). Effects of nalmefene on feeding in humans. Dissociation of hunger and palatability. Psychopharmacology (Berl) 100: 426-432.
89. Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A (2002). Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952: 188-199.